Effectiveness of sacubitril/valsartan for patients with cancer therapy‑related cardiac dysfunction: A systematic review of descriptive studies

Huang,Yun; Zhang,Yuyu; Xu,Weifeng; Fang,Chongbo; Zhou,Hua; Ma,Lili

doi:10.3892/ol.2023.13694

Effectiveness of sacubitril/valsartan for patients with cancer therapy‑related cardiac dysfunction: A systematic review of descriptive studies

Authors:
- Yun Huang
- Yuyu Zhang
- Weifeng Xu
- Chongbo Fang
- Hua Zhou
- Lili Ma
View Affiliations

Affiliations: Department of Pharmacy, Ningbo Medical Center Lihuili Hospital, Ningbo, Zhejiang 315040, P.R. China, Department of Cardiology, Ningbo Medical Center Lihuili Hospital, Ningbo, Zhejiang 315040, P.R. China
Published online on: February 2, 2023 https://doi.org/10.3892/ol.2023.13694
Article Number: 108

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present review assessed the effectiveness of sacubitril/valsartan in patients with cancer therapy‑related cardiac dysfunction (CTRCD). Studies that included patients with CTRCD treated with sacubitril/valsartan were retrieved from the Medline, Embase, Cochrane Library and ClinicalTrials databases. Only descriptive studies on sacubitril/valsartan for patients with CTRCD were included in this review; therefore, all variables were qualitatively analyzed. A total of five studies comprising 109 patients were included. The duration from anticancer therapy to heart failure (HF) or from HF to the use of sacubitril/valsartan exhibited interindividual variations. In patients with CTRCD who were treated with sacubitril/valsartan, the left ventricular ejection fraction improved, N‑terminal pro‑B‑type natriuretic peptide levels decreased and exercise tolerance improved, as indicated by the change in the New York Heart Association functional class. These clinical, echocardiographic and biochemical improvements were found for different dosages or treatment durations of sacubitril/valsartan. No difference was found between the baseline and follow‑up serum creatinine and potassium levels. These findings, which are limited to descriptive studies, support the effectiveness of sacubitril/valsartan in improving heart function following CTRCD.

View Figures

View References

1	Bloom MW, Hamo CE, Cardinale D, Ky B, Nohria A, Baer L, Skopicki H, Lenihan DJ, Gheorghiade M, Lyon AR and Butler J: Cancer Therapy-Related cardiac dysfunction and heart failure part 1: definitions, pathophysiology, risk factors, and imaging. Circ Heart Fail. 9:e0026612016. View Article : Google Scholar : PubMed/NCBI
2	Perez IE, Alam ST, Hernandez GA and Sancassani R: Cancer therapy-related cardiac dysfunction: An overview for the Clinician. Clin Med Insights Cardiol. 13:11795468198664452019. View Article : Google Scholar : PubMed/NCBI
3	Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F, Civelli M, Lamantia G, Colombo N, Curigliano G, et al: Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 131:1981–1988. 2015. View Article : Google Scholar : PubMed/NCBI
4	Rossi M, Carioli G, Bonifazi M, Zambelli A, Franchi M, Moja L, Zambon A, Corrao G, La Vecchia C, Zocchetti C and Negri E: Trastuzumab for HER2+ metastatic breast cancer in clinical practice: Cardiotoxicity and overall survival. Eur J Cancer. 52:41–49. 2016. View Article : Google Scholar : PubMed/NCBI
5	Ashif I, Mohammad KI, Sumit S, Ansari MA, Najmi AK, Ali SM, Ali J and Haque SE: Molecular mechanism involved in cyclophosphamide-induced cardiotoxicity: Old drug with a new vision. Life Sci. 218:112–131. 2019. View Article : Google Scholar : PubMed/NCBI
6	Expert Consensus for Multimodality Imaging Evaluation of Adult Patients during and after Cancer Therapy, . A Report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiog. 27:911–939. 2014. View Article : Google Scholar : PubMed/NCBI
7	Avila MS, Ayub-Ferreira SM, de Barros Wanderley MR Jr, das Dores Cruz F, Gonçalves Brandão SM, Rigaud VOC, Higuchi-Dos-Santos MH, Hajjar LA, Kalil Filho R, Hoff PM, et al: Carvedilol for prevention of chemotherapy-related cardiotoxicity: The CECCY trial. J Am Coll Cardiol. 71:2281–2290. 2018. View Article : Google Scholar : PubMed/NCBI
8	Huang S, Zhao Q, Yang ZG, Diao KY, He Y, Shi K, Shen MT, Fu H and Guo YK: Protective role of beta-blockers in chemotherapy-induced cardiotoxicity-a systematic review and meta-analysis of carvedilol. Heart Fail Rev. 24:325–333. 2018. View Article : Google Scholar : PubMed/NCBI
9	Fang K, Zhang Y, Liu W and He C: Effects of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use on cancer therapy-related cardiac dysfunction: A meta-analysis of randomized controlled trials. Heart Fail Rev. 26:101–109. 2020. View Article : Google Scholar : PubMed/NCBI
10	Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, et al: 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 37:2129–2200. 2016. View Article : Google Scholar : PubMed/NCBI
11	McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, et al: Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 371:993–1004. 2014. View Article : Google Scholar : PubMed/NCBI
12	Moher D, Liberati A, Tetzlaff J and Altman DG: Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. BMJ. 339:b25352009. View Article : Google Scholar : PubMed/NCBI
13	White PD and Myers MM: The classification of cardiac diagnosis. JAMA. 77:1414–1415. 1921. View Article : Google Scholar
14	Howick J, Chalmers I and Glasziou P: The oxford 2011 levels of evidence. Oxford, UK: Oxford Centre for Evidence-Based Medicine; 2011
15	Murad MH, Sultan S, Haffar S and Bazerbachi F: Methodological quality and synthesis of case series and case reports. BMJ Evid Med. 23:60–63. 2018. View Article : Google Scholar : PubMed/NCBI
16	Rashid M, Rajan AK, Chhabra M and Kashyap A: Levetiracetam and cutaneous adverse reactions: A systematic review of descriptive studies. Seizure. 75:101–109. 2020. View Article : Google Scholar : PubMed/NCBI
17	Sheppard CE and Anwar M: The use of sacubitril/valsartan in anthracycline-induced cardiomyopathy: A mini case series. J Oncol Pharm Pract. 25:1231–1234. 2019. View Article : Google Scholar : PubMed/NCBI
18	Gregorietti V, Fernandez TL, Costa D, Chahla EO and Daniele AJ: Use of Sacubitril/valsartan in patients with cardio toxicity and heart failure due to chemotherapy. Cardiooncology. 6:242020.PubMed/NCBI
19	Vecchis RD and Paccone A: A case series about the favorable effects of sacubitril/valsartan on anthracycline cardiomyopathy. SAGE Open Med Case Rep. 8:2050313X209521892020.PubMed/NCBI
20	Martín-García A, Díaz-Peláez E, Martín-García AC, Sánchez-González J, Ibáñez B and Sánchez PL: Myocardial function and structure improvement with sacubitril/valsartan in cancer therapy-induced cardiomyopathy. Rev Esp Cardiol (Engl Ed). 73:360–271. 2020.PubMed/NCBI
21	Martín-Garcia A, López-Fernández T, Mitroi C, Chaparro-Muñoz M, Moliner P, Martin-Garcia AC, Martinez-Monzonis A, Castro A, Lopez-Sendon JL and Sanchez PL: Effectiveness of sacubitril-valsartan in cancer patients with heart failure. ESC Heart Fail. 7:763–767. 2020. View Article : Google Scholar : PubMed/NCBI
22	Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, et al: 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur J Heart Fail. 18:891–975. 2016.(In Polish). View Article : Google Scholar : PubMed/NCBI
23	Hamo CE, Bloom MW, Cardinale D, Ky B, Nohria A, Baer L, Skopicki H, Lenihan DJ, Gheorghiade M, Lyon AR and Butler J: Cancer Therapy-related cardiac dysfunction and heart failure part 2: Prevention, treatment, guidelines, and future directions. Circ Heart Fail. 9:e0028432016. View Article : Google Scholar : PubMed/NCBI
24	Dadson K, Calvillo-Argüelles O, Thavendiranathan P and Billia F: Anthracycline-induced cardiomyopathy: Cellular and molecular mechanisms. Clin Sci (Lond). 134:1859–1885. 2020. View Article : Google Scholar : PubMed/NCBI
25	Wu QC, Bai BC, Tian C, Li D, Yu H, Song B, Li B and Chu X: The molecular mechanisms of cardiotoxicity induced by HER2, VEGF, and tyrosine kinase inhibitors: An updated review. Cardiovasc Drug Ther. 36:511–524. 2022. View Article : Google Scholar : PubMed/NCBI
26	Yu C, Li D, Li Z and Zhai C: Effect of sacubitril/valsartan on inflammation and oxidative stress in doxorubicin-induced heart failure model in rabbits. Acta Pharmaceutica. 71:473–484. 2020. View Article : Google Scholar : PubMed/NCBI
27	Huang CY, Chen JY, Kuo CH, Pai PY, Ho TJ, Chen TS, Tsai FJ, Padma VV, Kuo WW and Huang CY: Mitochondrial ROS-induced ERK1/2 activation and HSF2-mediated AT1 R upregulation are required for doxorubicin-induced cardiotoxicity. J Cell Physiol. 233:463–475. 2018. View Article : Google Scholar : PubMed/NCBI